Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer - Drug Trials For Money - Paid Clinical Trials

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Conditions:   Endometrial Endometrioid Adenocarcinoma;   Stage I Uterine Corpus Cancer AJCC v8;   Stage IA Uterine Corpus Cancer AJCC v8;   Stage IB Uterine Corpus Cancer AJCC v8;   Stage II Uterine Corpus Cancer AJCC v8
Interventions:   Radiation: Brachytherapy;   Radiation: External Beam Radiation Therapy;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022 / by / in
Comments